PuSH - Publication Server of Helmholtz Zentrum München

Schnell, O.* ; Agarwal, A.* ; Azizi, M.* ; Ballwieser, D.* ; Barnard‐Kelly, K.* ; Battelino, T.* ; Ballwieser, D.* ; Blüher, M. ; Bugianesi, E.* ; Cebrian, A.* ; Ceriello, A.* ; Choudhary, P.* ; Danne, T.* ; Dayan, C.M.* ; Prato, S.D.* ; Eckel, R.H.* ; Fioretto, P.* ; Garvey, T.* ; Green, J.B.* ; Heerspink, H.J.L.* ; Holman, R.R.* ; Itzhak, B.* ; Jacob, S.* ; Jhund, P.S.* ; Ji, L.* ; Judge, P.K.* ; Khunti, K.* ; Korenjak, M.* ; Krentz, A.J.* ; Lambrinou, E.* ; Libby, P.* ; Mader, J.K.* ; Mann, J.F.E.* ; Marx, N.* ; Mathieu, C.* ; McMurray, J.J.V.* ; Müller-Wieland, D.* ; Papanas, N.* ; Patel, D.* ; Pfeiffer, A.* ; Reger-Tan, S.* ; Rodbard, H.W.* ; Rosano, G.M.C.* ; Saboo, B.* ; Sato, N.* ; Solomon, S.D.* ; Standl, E.* ; Tacke, F.* ; Topsever, P.* ; Wanner, C.* ; Wharton, S.* ; Young, V.*

CVOT Summit Report 2025: Advances along the cardiovascular–kidney–metabolic disease continuum.

Cardiovasc. Diabetol. 25:142 (2026)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The 11th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 20–21, 2025. The Summit provided a multidisciplinary forum to review and discuss recent outcome trials investigating emerging pharmacological therapies targeting diseases of the cardiovascular–kidney–metabolic (CKM) continuum. This report highlights the unique developments of 2025 discussed during the Summit, including the first head-to-head CVOT (SURPASS-CVOT), the growing evidence base for combination therapies across the disease spectrum, new insights into the inflammatory component of the CKM syndrome, and relevant policy developments. The first part of this report summarizes pioneering clinical trials addressing combination therapy with finerenone and empagliflozin (CONFIDENCE), the oral glucagon-like peptide-1 (GLP-1) receptor agonists orforglipron (ATTAIN-1), and the aldosterone synthase inhibitor (ASI) baxdrostat (BaxHTN). The second part presents recent guideline and policy developments discussed by experts in endocrinology, diabetology, cardiology, nephrology, hepatology, and general practice. In addition, advances in medical technology, particularly in continuous glucose and ketone monitoring, are highlighted, as well as emerging therapies for diseases of the CKM continuum. These include pharmacological agents for a broad spectrum of metabolic disorders such as metabolic liver disease and type 1 Diabetes (T1D) alongside emphasis on the importance of early detection and innovative treatment strategies. The 12th Cardiovascular Outcome Trial Summit will be held virtually on 19–20 November 2026 (http://www.cvot.org).
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Keywords Summit ; Empagliflozin ; Clinical Trial ; Disease ; Multidisciplinary Approach ; Broad Spectrum ; Precision Medicine ; Type 2 Diabetes Mellitus; Beta-cell Function; Diabetes-mellitus; Agonists; Risk; Protection; Society; Obesity; Glp-1
ISSN (print) / ISBN 1475-2840
e-ISSN 1475-2840
Journal Cardiovascular Diabetology
Quellenangaben Volume: 25, Issue: 1, Pages: , Article Number: 142 Supplement: ,
Publisher Springer
Publishing Place Campus, 4 Crinan St, London N1 9xw, England
Reviewing status Peer reviewed
Institute(s) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)